Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:43:19.218Z.
Consensus retrieved: 2026-10-06T17:30:30.732Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:43:19.218Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b02f9201491092a18cecf2b81be2f5b28d52d90b5dbf9557ce71fef5bc65ed5
Forward PE Ratio (N/A) = Dated Quote Price ($1.08) / Consensus Forward EPS ($-2.25)
FORWARD PE RATIO
N/A
Tvardi Therapeutics, Inc.
Market Cap
$10.13M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $10.13M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
| Pluri Inc. (PLUR)vs › | $10.68M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.08, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.25 | $-2.89 – $-1.53 | 6 | n/m |
| 2027-12-31 | $-2.06 | $-3.35 – $-0.62 | 6 | n/m |
| 2028-12-31 | $-3.16 | $-6.97 – $-0.15 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
